Based on the NAMPT inhibitor CHS828 and EGFR inhibitor erlotinib, a compound 28 lacking the Michael receptor with a good double inhibitory effect were screened through the fusion of pharmacophore to inhibit the proliferation of several cancer cell lines in vitro. Here, NAMPT is linked to cancer.